Form 4: Teladoc Health Executive Daniel Trencher Reports Stock Transactions

Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, in a recent SEC filing.

Summary

• Daniel Trencher, Chief Strategy Officer of Teladoc Health, filed a Form 4 with the SEC detailing changes in beneficial ownership.
• The transactions include the acquisition of common stock through the conversion of performance stock units and restricted stock units on March 1, 2024.
• Trencher acquired 3,803, 364, 722, 1,179, 11,160, and 956 shares of common stock through the conversion of derivative securities.
• He also disposed of 6,780 shares of common stock on March 4, 2024, at a price of $14.516 per share to cover tax obligations.
• Following these transactions, Trencher directly owns 28,192 shares of common stock.
• He also holds 11,411 performance stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the executive's holdings.
• The sale of shares to cover tax obligations is a common practice and generally doesn't have a significant impact on the company's operations.

Key Dates